Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan and Melphalan Prior to Allogeneic Bone Marrow Transplantation for Advanced Hematologic Malignancies
NCT00014469Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2000
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan and melphalan in leukemia, myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Antileukemic potential, Transplantation-related morbidity and mortality and 1 more. Started Dec 2000; status: completed.
02
Drugs
busulfanmelphalan
03
Conditions
leukemiamyelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00014469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014469.